^
Association details:
Biomarker:No biomarker
Cancer:Clear Cell Renal Cell Carcinoma
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Subsequent therapy for clear cell histology…Useful in certain circumstances…Bevacizumab (category 2B)